Contact Us


September – 2015
Company establishment in Jakarta, Indonesia
July – 2016
Factory ground breaking ceremony (building production facilities for lyophilized powder injection and liquid injection)
September – 2016
Starting sales & marketing activities for importation of oncology and immunosuppressant products from CKD, South Korea
December – 2017

Completion of manufacturing construction in Cikarang, Indonesia

September – 2018
Obtaining GMP (Good Manufacturing Practice) certificate from BPOM (Indonesian FDA)
February – 2019
Obtaining Halal certificate from MUI (Indonesian Council of Ulama) with excellent category
July – 2019

Grand opening ceremony and manufacture inauguration with Kemenkes (Indonesian MoH)

First launch of targeted oral oncology product, Leukivec

August – 2020
Obtaining TKDN (Level of Domestic Content ) from Kemenperin (Indonesian MoI)
January – 2021

Starting Local CMO (Contract Manufacturing Organization) business

March – 2021

Signing the contract of exportation with one MENA Country

October – 2021

First exportation shipment to one MENA Country

August 2022
Inspected by SFDA (Saudi Food and Drug Authority) for GMP Compliances
September – 2022

Obtaining BMP (Company Benefit Weight) from Kemenperin (Indonesian MOI)

Obtaining ISO 14001:2015 (Environmental Management System) from SIS (Syndicate of International System) Certifications

Progress of Cytotoxic injection registration in ASEAN and GCC countries

December – 2023
Moving our HQ location to Sudirman Street, central business district in Jakarta
Our Shareholder

Meet CKD OTTO Shareholders

Key partners who support our commitment to pharmaceutical innovation and advances in cancer treatment.

Scroll to Top